CenterBook Partners LP Acquires New Holdings in Medpace Holdings, Inc. $MEDP

CenterBook Partners LP bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,296 shares of the company’s stock, valued at approximately $3,237,000.

Several other large investors have also recently made changes to their positions in the stock. Quent Capital LLC acquired a new position in Medpace during the third quarter worth $25,000. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Employees Retirement System of Texas acquired a new stake in shares of Medpace during the second quarter worth about $36,000. Root Financial Partners LLC acquired a new stake in shares of Medpace during the third quarter worth about $38,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after purchasing an additional 27 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In related news, CFO Kevin M. Brady sold 3,000 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at $3,542,100. This represents a 33.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 226,603 shares of company stock worth $137,084,658. Corporate insiders own 20.30% of the company’s stock.

Medpace Trading Up 4.2%

MEDP stock opened at $446.17 on Thursday. The stock has a market cap of $12.66 billion, a P/E ratio of 29.16, a PEG ratio of 2.05 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The company’s 50 day moving average is $560.49 and its two-hundred day moving average is $538.45.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same period last year, the firm posted $3.67 EPS. The company’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Barclays cut their price target on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a report on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the company from $462.00 to $419.00 in a report on Wednesday. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Leerink Partners lowered their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $483.45.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.